All In Biotech

NDA 208114 · Jazz Pharms INC

Defitelio

Defibrotide Sodium · Intravenous

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Mar 30, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Mar 30, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

21

4 Phase 3, 3 recruiting

FAERS reports

3,584

3,018 serious, 1,751 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 1, 2025.

DEFITELIO is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT). DEFITELIO is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT). ( 1 )

Mechanism: The mechanism of action of defibrotide sodium has not been fully elucidated. In vitro , defibrotide sodium enhances the enzymatic activity of plasmin to hydrolyze fibrin clots. Studies evaluating the pharmacological effects of defibrotide sodium on endothelial cells (ECs) were conducted primarily in the human microvascular endothelial cell line. In vitro , defibrotide sodium increased tissue plasminogen activator (t-PA) and thrombomodulin expression, and decreased von Willebrand factor (vWF) and plasminogen activator inhibitor‑1 (PAI-1) expression, thereby reducing EC activation and...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • DEFITELIO · DEFIBROTIDE SODIUM 200MG/2.5ML (80MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Defibrotide" as an intervention, any sponsor and status, largest first.

All 21 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,245
  • venoocclusive disease565
  • death465
  • venoocclusive liver disease347
  • multiple organ dysfunction syndrome343
  • intentional product use issue198
  • hypotension160
  • haemorrhage157
  • acute graft versus host disease140
  • gastrointestinal haemorrhage123
  • sepsis121
  • renal failure104

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201668
2017126
2018601
2019505
2020503
2021198
2022474
2023617
2024293
2025120
202679

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 97 on PubMed

Sponsor: Jazz Pharmaceuticals

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.